G Medical Innovations Overview
G Medical Innovations is a mobile and eHealth company that develops and markets medical-grade clinical and consumer health-monitoring solutions and offers end-to-end support for eHealth projects. The company has patented wireless technologies and proprietary information technology and service platforms. G Medical Innovations Medical Smartphone Jacket turns customers phones into mobile medical monitors that can provide comprehensive health profiling and vital-sign monitoring, including ECG, heart rate, respiration, etc. The company also offers the G Medical Patch (VSMS/GMP), a modular, easy-to-use, clinical-grade solution for monitoring patients throughout the healthcare lifecycle and intended for use by clinics, care residences, hospitals, and healthcare providers. The GMP streamlines and simplifies healthcare and patient monitoring by delivering continuous, real-time monitoring of a wide range of patient vital signs, including respiration and heart rate, blood pressure, body temperature, etc.
Cumulative Funding Raised Over Time ($)
$20.5MDec 2019
$30.8MNov 2017
Latest News
growth-negative
Headline
G Medical Innovations Holdings Ltd has received a letter from the Nasdaq Stock Market notifying the company that its ordinary shares will be delisted from the exchange due to its failure to comply with the minimum stockholders equity requirement. The companys ordinary shares are expected to be traded on the over-the-counter (OTC) Pink. The delisting does not affect the companys business, operations, or reporting requirements with the Securities and Exchange Commission. The CEO of G Medical Innovations expressed confidence in the long-term growth and success of the company and stated that they will work to get the shares listed back on a national securities exchange.
Public Trading
growth-positive
Revolutionizing Healthcare: G Medical Innovations shares future of remote monitoring and home testing
G Medical Innovations is making groundbreaking strides in mobile health and telemedicine solutions. The company offers comprehensive solutions and services for monitoring and managing health outcomes. They have three core revenue-generating verticals: Vitals Monitoring Business, At Home Tests Kits, and Research and Development activities. G Medical Innovations has partnered with Ideaology 360 to enhance their wholesale sales approach in the United States. They are also planning to introduce a blood pressure watch and an Oxygen saturation watch that can monitor blood pressure during sleep. These advancements in healthcare technology are expected to debut in the fourth quarter of 2023.
PartnersExpand
growth-positive
G MEDICAL INNOVATIONS WILL PROVIDE SERVICES TO VETERANS AND MILITARY PERSONNEL BY PARTNERING WITH RESILIENT SUPPORT SERVICES
G-Medical Innovations Holdings Ltd, a healthcare company specializing in remote patient monitoring solutions, has announced an agreement with Resilient Support Services Inc. to expand healthcare and remote patient monitoring capabilities for U.S. veterans and military personnel. The partnership aims to improve the medical care of veterans and the military community by providing access to near real-time patient information and analysis through G-Medical Innovations technology. The companys Prizma device will be used for remote patient monitoring, allowing for the monitoring of symptoms and immediate communication with healthcare providers. The partnership with Resilient Support Services Inc. will help protect and improve the care of veterans and military personnel. G-Medical Innovations is focused on developing mHealth and telemedicine solutions to empower consumers, patients, and providers in managing and improving health outcomes.
CustomersPartners
growth-positive
G Medical Innovations’ CEO Issues Update to Shareholders, August 2023
G Medical Innovations Holdings Ltd. has reported significant milestones and is on track to show revenue growth and gain profitability. The company has experienced growth in its monitoring services and is preparing to add revenue with its At Home Test Kits business unit. It has also announced several collaboration agreements for its Remote Health Monitoring (RHM) devices and services with AdventHealth of Central Florida and Memorial Hermann Health Systems. The company is also in negotiations with several large homecare service companies and large distributors for its devices and At Home Tests Kits. Additionally, the company has made significant changes to its corporate team.
CustomersPartnersManagement ChangesExpand
growth-negative
7 Doomed Stocks Destined for Disaster
The article discusses seven companies - G Medical Innovations, T2 Biosystems, Inpixon, The9, Moatable, Gaucho Group, and Soluna - whose stocks are considered high-risk and are recommended to be avoided by investors. These companies have seen significant declines in their equity value, with some facing potential delisting from the NASDAQ exchange due to their low share prices and market capitalization. The article also highlights the companies financial distress, with several facing the risk of bankruptcy in the next two years.
Public TradingManagement Changes
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $67.4M |
| Last funding | $9.6M |
| Stage | Public |
| Rounds | 5 |
| Investors | 2 |
Team Members
3
Employees: 11-50
Web & Social Links
| Website | gmedinnovations.com |
| Google Play | Google Play |
Locations
Prof. Hillel ve-Khanan Oppenheimer St 5, Rehovot, Israel
Karposh, Skopje, Karposh, Macedonia (FYROM)
18 Harcourt Rd, Admiralty, Hong Kong
Grand Cayman, Cayman Islands
4014 Medical Pkwy, Austin, TX 78756, USA
Photos & Videos
8 item(s)
G Medical Innovations Business
Business models
B2C, B2B, B2B2C
Product stage
Released
Employees
11-50
Sector
Health Tech & Life SciencesDigital HealthcarePatient Remote MonitoringMedical DevicesMedical MonitorsTarget Customer
Healthcare & Life SciencesHealthcarePatientsProvidersCore Technology
Semiconductors & ElectronicsWearablesSensingBiometricsTags (19)
vital-signssensorsphysiological-parametersearly-detectiontelehealthmonitoringhome-caremobile-applicationsmedical-deviceshospitalsdoctorspatientstelemedicineremote-monitoringe-healthhealthcare-providersmhealthdigital-healthcarebiometricsGeographic Markets
GlobalG Medical Innovations Financials
$67.4M
Total funding
Undisclosed
Capital raised
$9.6M
Last funding
Public
Funding stage
5
Total rounds
2
Investors
Cumulative Funding Raised Over Time ($)
$20.5MDec 2019
$30.8MNov 2017
Private Equity Funding
PIPE
Dec 2019
$20.5M
GEM Global Yield LLC
PIPE
Nov 2017
$10.3M
Undisclosed Investor(s)
Public Offering / Exit
POEvent
Apr 2023
Undisclosed
POEvent
Jun 2021
Undisclosed
DelistingEvent
Oct 2020
Undisclosed
POEvent
May 2017
Undisclosed
Mergers & Acquisitions
MNAEvent
Nov 2018
Undisclosed
G Medical Innovations Lifecycle
Cumulative Funding Raised Over Time
$20.5MDec 2019
$30.8MNov 2017
All Events
PIPE
Dec 2019
$20.5M
GEM Global Yield LLC
PIPE
Nov 2017
$10.3M
Undisclosed Investor(s)
POEvent
Apr 2023
Undisclosed
POEvent
Jun 2021
Undisclosed
DelistingEvent
Oct 2020
Undisclosed
POEvent
May 2017
Undisclosed
MNAEvent
Nov 2018
Undisclosed
G Medical Innovations News
41 articles
growth-negative
Headline
G Medical Innovations Holdings Ltd has received a letter from the Nasdaq Stock Market notifying the company that its ordinary shares will be delisted from the exchange due to its failure to comply with the minimum stockholders equity requirement. The companys ordinary shares are expected to be traded on the over-the-counter (OTC) Pink. The delisting does not affect the companys business, operations, or reporting requirements with the Securities and Exchange Commission. The CEO of G Medical Innovations expressed confidence in the long-term growth and success of the company and stated that they will work to get the shares listed back on a national securities exchange.
Public Trading
growth-positive
Revolutionizing Healthcare: G Medical Innovations shares future of remote monitoring and home testing
G Medical Innovations is making groundbreaking strides in mobile health and telemedicine solutions. The company offers comprehensive solutions and services for monitoring and managing health outcomes. They have three core revenue-generating verticals: Vitals Monitoring Business, At Home Tests Kits, and Research and Development activities. G Medical Innovations has partnered with Ideaology 360 to enhance their wholesale sales approach in the United States. They are also planning to introduce a blood pressure watch and an Oxygen saturation watch that can monitor blood pressure during sleep. These advancements in healthcare technology are expected to debut in the fourth quarter of 2023.
PartnersExpand
growth-positive
G MEDICAL INNOVATIONS WILL PROVIDE SERVICES TO VETERANS AND MILITARY PERSONNEL BY PARTNERING WITH RESILIENT SUPPORT SERVICES
G-Medical Innovations Holdings Ltd, a healthcare company specializing in remote patient monitoring solutions, has announced an agreement with Resilient Support Services Inc. to expand healthcare and remote patient monitoring capabilities for U.S. veterans and military personnel. The partnership aims to improve the medical care of veterans and the military community by providing access to near real-time patient information and analysis through G-Medical Innovations technology. The companys Prizma device will be used for remote patient monitoring, allowing for the monitoring of symptoms and immediate communication with healthcare providers. The partnership with Resilient Support Services Inc. will help protect and improve the care of veterans and military personnel. G-Medical Innovations is focused on developing mHealth and telemedicine solutions to empower consumers, patients, and providers in managing and improving health outcomes.
CustomersPartners
growth-positive
G Medical Innovations’ CEO Issues Update to Shareholders, August 2023
G Medical Innovations Holdings Ltd. has reported significant milestones and is on track to show revenue growth and gain profitability. The company has experienced growth in its monitoring services and is preparing to add revenue with its At Home Test Kits business unit. It has also announced several collaboration agreements for its Remote Health Monitoring (RHM) devices and services with AdventHealth of Central Florida and Memorial Hermann Health Systems. The company is also in negotiations with several large homecare service companies and large distributors for its devices and At Home Tests Kits. Additionally, the company has made significant changes to its corporate team.
CustomersPartnersManagement ChangesExpand
growth-negative
7 Doomed Stocks Destined for Disaster
The article discusses seven companies - G Medical Innovations, T2 Biosystems, Inpixon, The9, Moatable, Gaucho Group, and Soluna - whose stocks are considered high-risk and are recommended to be avoided by investors. These companies have seen significant declines in their equity value, with some facing potential delisting from the NASDAQ exchange due to their low share prices and market capitalization. The article also highlights the companies financial distress, with several facing the risk of bankruptcy in the next two years.
Public TradingManagement Changes
growth-negative
G Medical Innovations Holdings Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification
G Medical Innovations Holdings Ltd. has received a notice from Nasdaq Stock Market indicating that the company is not in compliance with the minimum bid price requirement for continued listing. The company has been granted a 180-day period to regain compliance. If the closing bid price of its ordinary shares is at least $1.00 for a minimum of ten consecutive business days during this period, the company will regain compliance. If not, the company may be eligible for an additional 180-day compliance period. G Medical Innovations Holdings is a healthcare company engaged in the development of mHealth and telemedicine solutions and monitoring service platforms.
Public Trading
growth-negative
G Medical Innovations Holdings Ltd. Announces Receipt of Nasdaq Hearings Panel’s Decision to Grant Exception for Continued Listing
G Medical Innovations Holdings Ltd. has received notice from the Hearings Panel of Nasdaq that it can continue its listing on Nasdaq, subject to certain conditions. The company had previously received a deficiency letter from Nasdaq for non-compliance with the minimum shareholders equity requirement. The Panel has granted an exception period until August 4, 2023, during which the company must provide unaudited interim financial statements and demonstrate compliance with the equity requirement. The Panel reserves the right to reconsider the exception based on any events that may affect compliance. G Medical Innovations is a healthcare company focused on developing mHealth and telemedicine solutions, including its Prizma medical device and at-home laboratory testing kits. The company aims to empower consumers, patients, and providers to monitor and manage health outcomes.
Public Trading
growth-positive
G MEDICAL UPDATES ON PATIENT ENROLLMENT GROWTH FOR ITS HOME MONITORING SERVICES OF 194% FROM JANUARY THROUGH APRIL 2023, AS COMPARED TO THE SAME PERIOD IN 2022
G Medical Innovations Holdings Ltd. has experienced a 194% growth in patient enrollment for its home monitoring services between January and April 2023. The increase is attributed to the growing demand for homecare monitoring. The company has signed agreements with AdventHealth and MiCare Path to integrate their software platforms and visualization tools into its devices, expanding its remote patient monitoring and remote therapeutic monitoring solutions. In addition, G Medical entered the at-home laboratory testing market in the second half of 2022 and expects consumers to be able to purchase its test kits in the third quarter of 2023. The company has completed an equity capital raise of $9.6 million, with CEO Dr. Yacov Geva personally investing $1 million. The raise will support the companys continued growth.
CustomersPartnersInvestment
G Medical Innovations Holdings Ltd. Announces Closing of Public Offering
G Medical Innovations Holdings Ltd. Announces Pricing of Public Offering
G MEDICAL INNOVATIONS AND ADVENTHEALTH IN JOINT COLLABORATION TO PROVIDE INNOVATIVE REMOTE PATIENT MONITORING SOLUTIONS FOR ADVENTHEALTH PATIENTS IN CENTRAL FLORIDA
growth-positive
G MEDICAL INNOVATIONS AND MICARE PATH ANNOUNCE JOINT COLLABORATION TO PROVIDE INNOVATIVE REMOTE PATIENT MONITORING SOLUTIONS GLOBALLY
G Medical Innovations Holdings Ltd. and MiCare Path have announced a collaboration to integrate their respective solutions for remote patient monitoring. G Medical Innovations hardware devices will be integrated with MiCares software platform and visualization tools. The partnership aims to transform the healthcare industry by leveraging technology and providing patient-centered care. Under the agreement, G Medical Innovations will be responsible for the server integration of its devices into MiCare’s platform, and MiCare will handle all support and IT integration related to their patient application. The agreement will last until December 31, 2024, with automatic renewals each year.
Partners
G Medical Innovations Holdings Ltd Announces Nasdaq Staff Listing Determination; Plans to Request Hearing
G Medical Innovations announces receipt of patent from USPTO for vital signs sensors
G Medical Innovations announces receiving notice of patent issuance from the USPTO for vital signs sensors
G Medical Innovations to announce receiving of 2 (two) granted patents from the USPTO for its Prizma care and other physiological sensors developed by the company.
Growth-Negative
G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) Announces Receipt of Notice of Deficiency with Nasdaq Continued Listing Requirements
G Medical Innovations Holdings Ltd., a telehealth and medical device company, has received a notice from Nasdaq Stock Market LLC stating that the company is no longer in compliance with the minimum shareholders’ equity requirement for continued listing on the Nasdaq Capital Market. The company did not meet the alternative compliance standards relating to the market value of listed securities or net income from continuing operations. The company has until January 6, 2023, to submit a plan to regain compliance. If the plan is accepted, Nasdaq can grant an extension of up to 180 calendar days from the date of the letter to evidence compliance.
Public Trading
G Medical Innovations Announces First Half 2022 Financial Results and Provides Business Update
growth-positive
G Medical Innovations to provide numerous at-home testing kits to consumers
G Medical Innovations has developed 31 at-home health test kits that will be available online and in retail sites and pharmacies in the U.S. The tests include screening for various health issues, such as monkeypox, colon cancer, thyroid issues, and STDs. Results are available within 48 hours from when a kit is received by the companys CLIA-certified labs. The tests will cost between $50 and $260 depending on complexity.
Customers
growth-positive
G Medical Innovations is introducing a Monkeypox consumer home health test kit, along with 30 new direct to consumer home health testing kits with 24 to 48 hours results
G Medical Innovations Holdings Ltd. has developed 31 different at-home health test kits that will be available to consumers in Q4-2022. The kits cover a range of health issues and utilize non-invasive testing methods. The company expects to serve millions of Americans and aims to focus on home-based health care systems. The tests will be available for purchase online and at retail locations and pharmacies across the United States. The pricing of the kits ranges from $50 to $260. G Medical Innovations is a healthcare company engaged in the development of mHealth and telemedicine solutions and monitoring service platforms.
CustomersExpand
G Medical Innovations is introducing a Monkeypox consumer home health test kit, along with 30 new direct to consumer home health testing kits with 24 to 48 hours results
growth-positive
G Medical Innovations is introducing affordable, new direct to consumer home health testing kits with quick results
G Medical Innovations Holdings Ltd. has announced that its subsidiary, G. Medical Health and Wellness, Inc., has developed seven different at-home health tests. The tests, which cover food sensitivity, indoor/outdoor allergies, thyroid functioning, testosterone levels, HbA1C, and HPV, will be available for purchase online and at retail locations and pharmacies during Q3-2022. The tests use FDA registered components and prices range from $50-$260. The company expects to serve millions of Americans with these tests.
CustomersExpand
growth-positive
G Medical Innovations is introducing affordable, new direct to consumer home health testing kits with quick results
G Medical Innovations Holdings Ltd. has developed seven different at-home health testing kits that will be available for purchase by consumers in Q3-2022. The tests cover various health issues such as food sensitivity, allergies, HPV, thyroid functioning, testosterone levels, and hemoglobin A1C. The kits utilize FDA registered components and provide results within days. The company aims to serve millions of Americans with these testing kits. The tests use non-invasive methods such as saliva, swab sticks, and finger pricking for sample collection. Prices for the kits range from $50 to $260. G Medical Innovations is a healthcare company focused on developing mHealth and telemedicine solutions and monitoring service platforms. They have been offering patient home care monitoring for over 30 years and are now expanding into comprehensive home testing solutions.
CustomersExpand
Growth-Negative
G Medical Innovations Holdings Ltd. (Nasdaq: GMVD) Announces Receipt of Nasdaq Minimum Bid Price Notification
G Medical Innovations Holdings Ltd. has received a notice from Nasdaq Stock Market LLC, indicating that the company is not in compliance with the minimum bid price requirement for continued listing. The company has been granted a period of 180 calendar days to regain compliance with the minimum bid price requirement. If the company fails to demonstrate compliance by the allotted compliance period(s), Nasdaq’s staff will notify the company that its ordinary shares are subject to delisting.
Public Trading
growth-negative
G Medical plunges on first day on Nasdaq
G Medical Innovations Holdings Ltd. raised $15 million at a post-money valuation of $65 million through an offering on Nasdaq. The share price fell 30% on the first day of trading, bringing the companys market cap down to $45 million. The offering allowed the company to become listed on Nasdaq after being delisted from the Australian Securities Exchange. G Medical has developed a mobile app for monitoring vital signs and has received FDA approval for its products. The company had a decline in revenue in 2020 but narrowed its loss. The founder, Yacov Geva, previously founded and sold his stake in LifeWatch.
InvestmentPublic Trading
growth-negative
Israeli Digital Health Startup G Medical Innovations Withdraws $30M US IPO
G Medical Innovation has withdrawn its plans for an IPO to raise $30 million. This is the companys second attempt to go public in the US. They are an early commercial-stage healthcare company developing app-based connected medical devices. Their current product offerings include the Prizma medical device and the Extended Holter Patch System. The company reported $5 million in revenue for the 12 months ended June 30, 2020.
Public Trading
growth-positive
גי מדיקל שואפת לקבל בנאסד"ק שווי גבוה פי 13 מזה שבאוסטרליה
G Medical, a medical device company specializing in remote patient monitoring and telemedicine, is set to become a public company in the US after completing its initial public offering (IPO) on NASDAQ. The company plans to raise about $30 million by issuing 5 million shares, with a price range of $5-7 per share. The IPO could potentially increase the fundraising volume by $10 million. Assuming the IPO is carried out at the middle of the price range per share, G Medicals market value will reach about $360 million. The company recently entered the coronavirus market as its products can examine blood oxygen saturation, fever, and EKG.
InvestmentPublic Trading
growth-positive
G MEDICAL INNOVATIONS HOLDINGS LTD. ANNOUNCES FILING OF SEC REGISTRATION STATEMENT FOR PROPOSED NASDAQ INITIAL PUBLIC OFFERING
G Medical Innovations Holdings Ltd. has filed a registration statement on Form F-1 with the SEC for its proposed initial public offering (IPO) on the Nasdaq Global Market. The company is a telehealth, medical device, and remote patient monitoring company providing clinical-grade solutions. The proposed offering is for US$30,000,000, with a price range of between US$5.00 and US$7.00 per share. Boustead Securities, LLC and Fosun Hani Securities Limited are acting as co-lead underwriters for the IPO. The offering is subject to market conditions, and there is no assurance of its completion or the final terms. A registration statement has been filed with the SEC but has not yet become effective.
Public Trading
growth-positive
G Medical receives TGA approval for device to continuously monitor cardiac patients
G Medical Innovations has received approval from the Therapeutics Goods Administration for its extended holter patch for continuous cardiac monitoring. The approval marks a significant milestone for the company as the patch now complies with all relevant Australian medical and safety requirements. G Medical is also pursuing regulatory approvals in other target markets, including the United States. The companys CEO stated that their medical devices and telehealth platforms are recognized as cost-effective and scalable solutions that can ease the burden on healthcare systems. The extended holter patch is part of the modular vital signs monitoring system and provides a continuous, 14-day recording of a six-channel electrocardiogram.
Customers
growth-positive
Remote monitoring co G Medical again mulls Nasdaq listing
G Medical Innovations Holdings Ltd., an Israeli remote medical monitoring solutions company, is preparing to list on Nasdaq after expanding its activities due to the Covid-19 crisis. The companys product can test whether a patient is likely to be endangered by Covid-19 by measuring oxygen saturation, temperature, and EKG. G Medicals product is approved for marketing with a doctors prescription and has received FDA approval for an Over the Counter (OTC) version. The company is optimistic about its chances of success in listing on Nasdaq and is interested in developing additional tests for remote monitoring. The article was published on April 26, 2020.
Public TradingExpand
growth-positive
G Medical Innovations receives $20.5M to grow US, international remote monitoring business
G Medical Innovations, a Cayman Islands-based company that develops real-time vital signs monitoring tools, has raised $20.5 million in investments from Luxembourg-based investment group GEM Global. The funding will be used to expand the companys US and international sales force, with plans to add 20 new representatives by the end of next year and a target of 60 by 2022. The companys products, which include the Prizma Medical Smartphone Case and the Vital Signs Monitoring System and G Medical Patch, allow for continuous monitoring of patients health metrics.
InvestmentExpand
growth-positive
Israeli diagnostics co G Medical set for Nasdaq offering
Israeli medical diagnosis company G Medical Innovations Holdings Ltd. has submitted a prospectus for a Nasdaq offering. The company offers medical monitoring solutions and has developed a heart diagnostic device connected to a smartphone and a sticker for monitoring patients in hospital beds. The offering will be used to enlarge the sales and marketing team, develop next-generation products, and for working capital and general uses. G Medical plans to issue American Depositary Shares (ADS) on the ASX. The underwriting for the offering is HC Wainwright. The company had $3.1 million in revenue in 2018 and a net loss of $17 million.
Public TradingInvestment
G Medical Innovations secures first US commercial orders valued at almost US$22 million
G Medical Innovations granted trading halt pending US purchase order update
G Medical Innovations acquires Telerhythmics, expands US footprint
growth-positive
G Medical Innovations' CEO Yacov Geva hands over more cash to fund company's growth
Yacov Geva, CEO and president of G Medical Innovations, has provided a $10 million loan facility to the company. This follows his initial $3 million loan in May. The loan will be used for G Medicals growth and expansion plans, including working capital, inventory, and medical devices. The terms of the loan are considered better than other financing options available to the company. In addition to the loan, Geva purchased 1.036 million fully paid ordinary shares in G Medical. The company has also received regulatory approvals for its China processing facility, allowing it to boost its global production capacity. G Medical has secured FDA approval for over 48 medical devices. The news has had a positive impact on the companys share price, which increased by over 17%.
Investment
G Medical Innovations receives regulatory approval for China production facility
G Medical Innovations moving towards US public offering and NASDAQ listing
growth-positive
iTWire - G Medical's new e-store lets consumers buy Prizma medical smartphone case direct
G Medical Innovations, a medical technology company, has launched an online store for its Prizma Medical Smartphone Case, which turns smartphones into medical monitoring devices. The Prizma has received regulatory approvals from authorities such as the FDA and TGA, and can monitor a range of biometric measurements in real-time. Users can create patient profiles, track their vital signs, and share test results with caregivers and medical professionals. The launch of the online store marks the first time that consumers can directly purchase the Prizma in approved countries. The company has also received certifications from the TGA and MEDSAFE, allowing the Prizma to be sold as a medical device in Australia, New Zealand, and other countries. These certifications have opened up the global market for the Prizma and expedited commercial discussions with potential partners.
CustomersPartners
growth-positive
G Medical Innovaions raises $10m to support Prizma medical smartphone case
G Medical Innovations has raised $10.3 million to support the commercialization of its Prizma medical smartphone accessory and case. The round was oversubscribed, with funds raised through the sale of shares. The Prizma case allows users to use their smartphone as a mobile medical monitor and record vital signs into a cloud-based storage solution. The data can be shared with healthcare professionals and caretakers. G Medical Innovations has received CE Mark approval in the EU and FDA clearance for the Prizma case.
Investment
G Medical Innovations shares ride higher after signing US$405M deal
G Medical Innovations Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 37 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 13 classification IDs that could be used for matching.
G Medical Innovations Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 93/100 |
| Missing | markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 515169696 |
| Crunchbase | g-medical-innovations |
| Creator | Sharon Zaks |
| Creator email | sharon1337@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-07-07T00:00:00.000Z |
| Created | 2017-06-14T00:00:00.000Z |
| Status detail | Public on NASDAQ on Jun, 2021;Public on ASX on Apr, 2023; |